End-of-day quote
Shenzhen S.E.
03:30:00 10/05/2024 am IST
|
5-day change
|
1st Jan Change
|
12.07
CNY
|
-0.82%
|
|
+1.77%
|
-5.11%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,379
|
6,637
|
8,188
|
9,948
|
10,952
|
10,393
|
-
|
-
|
Enterprise Value (EV)
1 |
7,379
|
6,637
|
8,188
|
9,948
|
10,952
|
10,393
|
10,393
|
10,393
|
P/E ratio
|
14.7
x
|
10.1
x
|
12.7
x
|
16.7
x
|
17.7
x
|
15.4
x
|
12.4
x
|
10.8
x
|
Yield
|
3.26%
|
3.52%
|
-
|
-
|
2.36%
|
2.65%
|
1.49%
|
3.81%
|
Capitalization / Revenue
|
2.02
x
|
2.04
x
|
-
|
-
|
2.74
x
|
2.37
x
|
2.03
x
|
1.84
x
|
EV / Revenue
|
2.02
x
|
2.04
x
|
-
|
-
|
2.74
x
|
2.37
x
|
2.03
x
|
1.84
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
11.8
x
|
8.13
x
|
8.01
x
|
6.03
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
2.11
x
|
1.79
x
|
-
|
-
|
1.99
x
|
1.75
x
|
1.56
x
|
1.45
x
|
Nbr of stocks (in thousands)
|
8,24,515
|
8,01,278
|
8,61,029
|
8,16,739
|
8,61,029
|
8,61,029
|
-
|
-
|
Reference price
2 |
8.950
|
8.283
|
9.510
|
12.18
|
12.72
|
12.07
|
12.07
|
12.07
|
Announcement Date
|
26/02/20
|
26/02/21
|
25/02/22
|
27/02/23
|
29/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3,647
|
3,260
|
-
|
-
|
3,999
|
4,391
|
5,108
|
5,634
|
EBITDA
1 |
-
|
-
|
-
|
-
|
931.4
|
1,278
|
1,297
|
1,724
|
EBIT
1 |
602.1
|
759.3
|
-
|
-
|
714.1
|
778
|
961
|
1,104
|
Operating Margin
|
16.51%
|
23.29%
|
-
|
-
|
17.86%
|
17.72%
|
18.81%
|
19.6%
|
Earnings before Tax (EBT)
1 |
603.4
|
753
|
-
|
-
|
708
|
775
|
959.2
|
1,100
|
Net income
1 |
520.4
|
653.5
|
614
|
646.4
|
618.9
|
675.9
|
840.6
|
977
|
Net margin
|
14.27%
|
20.04%
|
-
|
-
|
15.48%
|
15.39%
|
16.46%
|
17.34%
|
EPS
2 |
0.6075
|
0.8175
|
0.7500
|
0.7300
|
0.7200
|
0.7850
|
0.9750
|
1.120
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.2917
|
0.2917
|
-
|
-
|
0.3000
|
0.3200
|
0.1800
|
0.4600
|
Announcement Date
|
26/02/20
|
26/02/21
|
25/02/22
|
27/02/23
|
29/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
14.4%
|
17.4%
|
14.2%
|
-
|
11.7%
|
11.4%
|
12.6%
|
13.4%
|
ROA (Net income/ Total Assets)
|
9.78%
|
11.6%
|
-
|
-
|
-
|
7.8%
|
8.65%
|
9.8%
|
Assets
1 |
5,322
|
5,649
|
-
|
-
|
-
|
8,665
|
9,718
|
9,969
|
Book Value Per Share
2 |
4.250
|
4.630
|
-
|
-
|
6.400
|
6.900
|
7.750
|
8.340
|
Cash Flow per Share
2 |
0.6200
|
0.6100
|
-
|
-
|
0.9200
|
1.050
|
1.160
|
1.520
|
Capex
1 |
335
|
332
|
-
|
-
|
-
|
375
|
375
|
375
|
Capex / Sales
|
9.19%
|
10.17%
|
-
|
-
|
-
|
8.54%
|
7.34%
|
6.66%
|
Announcement Date
|
26/02/20
|
26/02/21
|
25/02/22
|
27/02/23
|
29/03/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -5.11% | 1.44B | | +30.38% | 684B | | +29.21% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.91% | 240B | | +9.08% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|